IL6 and COVID-19: Finally, another IL-6 antagonist that was deemed of interest for severe COVID-19 patients is siltuximab, an FDA approved chimeric monoclonal antibody used for the management of neoplastic diseases such as metastatic renal cell cancer and Castleman’s disease (https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant).